Six-step etoposide desensitization protocol: A pediatric, adolescent, and young adult case series.

Etoposide administration can be complicated by hypersensitivity reactions. Desensitization may provide a strategy to prevent hypersensitivity recurrence. One challenge with desensitization is regimen complexity.

Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies.

Introduction: Etoposide is critical in treating pediatric cancers, although hypersensitivity can be severe and treatment-limiting. Reported rates of hypersensitivity range from 2% to 51%. Hypersensitivity data for etoposide phosphate, a newer product, are lacking.

Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge.

Background: Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after discharge. The objectives of this study were to evaluate the impact of the initiative on location and timing of first palivizumab dose, patient adherence, reimbursement, acquisition cost and RSV-positive hospital readmissions.

Antithrombin III Doses Rounded to Available Vial Sizes in Critically Ill Pediatric Patients.

Objectives: Children have decreased levels of antithrombin III (AT III) compared to adults. These levels may be further decreased during acute illness. Administration of exogenous AT III can increase anticoagulant efficacy.